GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma

Inclusion Criteria: * Age 18 years or older. * Histologically or cytologically confirmed primary refractory or relapsed/progressive large B-cell lymphoma. * Expected survival of more than 3 months. * CD19-positive B-cell lymphoma confirmed by flow cytometry or immunohistochemistry. * ECOG performance status of 0 to 2 or KPS score greater than 80. * Adequate venous access for leukapheresis or peripheral blood collection, with no contraindication to blood cell separation. * White blood cell count ≥ 1 × 10\^9/L and lymphocyte count ≥ 0.3 × 10\^9/L. * INR \< 1.7 or prothrombin time prolonged by less than 4 seconds above the normal value. * ALT and AST ≤ 2.5 × upper limit of normal. * Total bilirubin ≤ 2.0 mg/dL, equivalent to 34.2 μmol/L. * Able to understand and voluntarily sign the written informed consent form. Exclusion Criteria: * Pregnant or breastfeeding women. * Active hepatitis B virus or hepatitis C virus infection. * HIV/AIDS infection. * Any uncontrolled active infection. * Systemic corticosteroid use within 2 weeks before signing informed consent, except inhaled corticosteroids. * Active cardiac disease requiring treatment or poorly controlled hypertension. * Unstable or active ulcer disease or gastrointestinal bleeding. * History of organ transplantation or currently awaiting organ transplantation. * Central nervous system involvement by lymphoma. * Current participation in another clinical trial. * Any other condition that, in the investigator's judgment, makes …